medigraphic.com
Instituto Nacional de Salud Pública

2016, Number 2

<< Back Next >>

salud publica mex 2016; 58 (2)

HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico

Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, Castle PE, Robles C, Lazcano-Ponce E

Language: English
References: 23
Page: 211-219
PDF size: 475.98 Kb.


ABSTRACT

Objective. To outline the design of a clinical trial to evaluate the impact of HPV vaccination as part of a hrHPV-based primary screening program to extend screening intervals. Materials and methods. A total of 18,000 women aged 25-45 years, attending the regular cervical cancer-screening program in primary health care services in Tlalpan, Mexico City, will be invited to the study. Eligible participants will be assigned to one of three comparison groups: 1) HPV16/18 vaccine and hrHPV-based screening; 2) HPV6/11/16/18 vaccine and hrHPV-based screening; 3) Control group who will receive only hrHPV-based screening. Strict surveillance of hrHPV persistent infection and occurrence of precancerous lesions will be conducted to estimate safety profiles at different screening intervals; participants will undergo diagnosis confirmation and treatment as necessary. Conclusion. The FASTER-Tlalpan Study will provide insights into new approaches of cervical cancer prevention programs. It will offer valuable information on potential benefits of combin-HPVing HPV vaccination and hrHPV-based screening to safety extend screening intervals.


REFERENCES

  1. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer. 2013. [Accessed on December 18 2015] Available at: http:// globocan.iarc.fr

  2. Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report 2015- 12-23. [Acceded 2016 January 2016]. Available at: http://www.hpvcentre.net/statistics/reports/XWX.pdf

  3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.

  4. de Sanjose S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-56.

  5. Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev 2013;22:553-60.

  6. Cervical Cancer Action. Progress in cervical cancer prevention.The CCA report card 2015. [Publication Spotlight] 2015 [Accessed on 2016 January 13] 28 pp. Available at: http://www.cervicalcanceraction.org/pubs/ CCA_reportcard_low-res_2015.pdf

  7. World Health Organization. Meeting of the immunization Strategic Advisory Group of Experts, November 2006--conclusions and recommendations. Wkly Epidemiol Rec [serie en internet] 2007 [accessed on 2014 Octubre];82:1-16. Available at: http://www.who.int/wer/2007/ wer8201_02.pdf

  8. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine. JNCI 2004;96: 604-15.

  9. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135-45.

  10. Muñoz N, Mendez F, Posso H, Molano M, van den Brule AJ, Ronderos M, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004;190:2077-87.

  11. Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 2014;384:2213-27.

  12. Luna J, Plata M, Gonzalez M, Correa A, Maldonado I, Nossa C, et al. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil in adult women. PLoS one 2013;8:e83431.

  13. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Crossprotective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:781-9.

  14. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014;14:958-66.

  15. Bosch FX, Robles C, Diaz M, Arbyn M, Baussano I, Clavel C, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 2015. [advance online publication] DOI: 10.1038/ nrclinonc.2015.146.

  16. Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012;7(1):38.

  17. Brotherton JML, Malloy M, Budd AC, Saville M, Drennan KT, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia. Papillomavirus Research. 2015; 1:59-73.

  18. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 2015;16:775-86.

  19. Instituto Nacional de Estadística, Geografía e Informática. [sitio de internet] Censo de Población y vivienda 2010. Accessed on [2015 November 24]. México, D.F: INEGI 2012. Available at: http://www3.inegi.org. mx/sistemas/TabuladosBasicos/Default.aspx?c=27302&s=est

  20. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004;91:942-53.

  21. Lu B, Kumar A, Castellsague X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis 2011;11:13.

  22. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007;177:469-79.

  23. Comisión Federal para la Protección contra Riesgos Sanitarios. Consulta de Registros Sanitarios 2015. [Accessed on 2015 July 15]. Available at: http://189.254.115.245/BuscadorPublicoRegistrosSanitarios/Busqueda- RegistroSanitario.aspx




2020     |     www.medigraphic.com